Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2021 / N 3

Фиксированная комбинация индапамид/периндоприл как стартовая терапия артериальной гипертонии
О.А. Полякова, А.И. Кочетков, О.Д. Остроумова

References

1. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016 Aug;134(6):441-50.
2. Volpe M, Camm J, Coca A, Unger T. The cardiovascular continuum refined: a hypothesis. Blood Pressure 2010 Oct;19(5):273-7.
3. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B; Blood Pressure Lowering Treatment Trialists’ Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. Journal of Hypertension 2011 Jan;29(1):4-16.
4. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet 2016 Mar;387(10022):957-67.
5. Tocci G, Presta V, Ferri C, Redon J, Volpe M. Blood pressure targets achievement according to 2018 ESC/ESH guidelines in three European excellence centers for hypertension. High Blood Pressure & Cardiovascular Prevention 2020 Feb;27(1):51-9.
6. Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J, Perk J, Roy C, Banegas JR, Rodriguez-Artalejo F, Halcox JP. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study. International Journal of Cardiology 2016 Sep;218:83-8.
7. Balanova YuA, Shalnova SA, Imayeva AE, Kapustina AV, Muromtseva GA, Yevstifeyeva SE, Tarasov VI, Redko AN, Viktorova IA, Prishchepa NN, Yakushin SS, Boytsov SA, Drapkina OM on behalf of ESSAY-RF-2 researchers. Prevalence, awareness, treatment and control of hypertension in Russian Federation (data of observational ESSE-RF-2 study). Rational Pharmacotherapy in Cardiology 2019;15(4):450-66 (In Russian).
8. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S; PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013 Sep;310(9):959-68.
9. Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, Tsabedze L, Supiyev A, Sturua L, Bahendeka SK, Sibai AM, Quesnel-Crooks S, Norov B, Mwangi KJ, Mwalim O, Wong-McClure R, Mayige MT, Martins JS, Lunet N, Labadarios D, Karki KB, Kagaruki GB, Jorgensen JMA, Hwalla NC, Houinato D, Houehanou C, Msaidié M, Guwatudde D, Gurung MS, Gathecha G, Dorobantu M, Damasceno A, Bovet P, Bicaba BW, Aryal KK, Andall-Brereton G, Agoudavi K, Stokes A, Davies JI, Bärnighausen T, Atun R, Vollmer S, Jaacks LM. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1,1 million adults. The Lancet 2019 Aug;394(10199):652-62.
10. Bruyn E, Nguyen L, Schutte AE, Murphy A, Perel P, Webster R. Implementing single-pill combination therapy for hypertension: a scoping review of key health system requirements in 30 low- and middle-income countries. Global Heart 2022 Jan;17(1):6.
11. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2013 Jul;34(28):2159-219.
12. Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. European Heart Journal 2018 Oct;39(40):3654-61.
13. Tocci G, Presta V, Citoni B, Figliuzzi I, Bianchi F, Ferrucci A, Volpe M. Blood pressure target achievement under monotheraphy: a real-life appraisal. High Blood Pressure & Cardiovascular Prevention 2020 Dec;27(6):587-96.
14. Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, De Luca N, Fallo F, Ferri C, Morganti A, Muiesan ML, Sarzani R, Sechi L, Virdis A, Tocci G, Trimarco B, Filippi A, Mancia G; Italian Society of Hypertension. 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. High Blood Pressure & Cardiovascular Prevention 2013 Mar;20(1):45-52.
15. Russian Society of Cardiology. Arterial hypertension in adults. Clinical guidelines, 2020. Russian Journal of Cardiology 2020;25(3):149-218 (In Russian).
16. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip G, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018 Sep;39(33):3021-104.
17. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018 Jun;71(6):e13-e115.
18. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020;75(6):1334-57.
19. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 2002 Mar;359(9311):995-1003.
20. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet 2004 Jun;363(9426):2022-31.
21. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 2005 Sep;366(9489):895-906.
22. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The New England Journal of Medicine 2008 Dec;359(23):2417-28.
23. Tocci G, Citoni B, Presta V, Leoncini G, Viazzi F, Bonino B, Volpe M, Pontremoli R. Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. Internal and Emergency Medicine 2020 Apr;15(3):373-9.
24. Tsioufis K, Kreutz R, Sykara G, van Vugt J, Hassan T. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. Journal of Hypertension 2020 Jun;38(6):1016-28.
25. Buda V, Andor M, Petrescu L, Cristescu C, Baibata DE, Voicu M, Munteanu M, Citu I, Muntean C, Cretu O, Tomescu MC. Perindopril induces TSP-1 expression in hypertensive patients with endothelial dysfunction in chronic treatment. International Journal of Molecular Science 2017 Feb;18(2):348.
26. Brugts JJ, Ferrari R, Simoons ML. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Review of Cardiovascular Therapy 2009 Apr;7(4):345-60.
27. Louis WJ, Conway EL, Krum H, Workman B, Drummer OH, Lam W, Phillips P, Howes LG, Jackson B. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Clinical and Experimental Pharmacology & Physiology. Supplement 1992;19:55-60.
28. Louis WJ, Workman BS, Conway EL, Worland P, Rowley K, Drummer O, McNeil JJ, Harris G, Jarrott B. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. Journal of Cardiovascular Pharmacology 1992 Sep;20(3):505-11.
29. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integrated Blood Pressure Control 2014 Jul;7:35-47.
30. Campbell DB. The possible mode of action of indapamide: a review. Current Medical Research and Opinion 1983;8(Suppl 3):9-24.
31. Ostroumova OD, Polyakova OA, Listratov AI, Logunova NA, Gorokhova TV. Thiazide and thiazide-like diuretics: how to make the right choice? Kardiologiia 2022;62(1):89-97 (In Russian).
32. Circelli M, Nicolini G, Egan CG, Cremonesi G. Efficacy and safety of delapril/indapamide compared to different ACE-inhibitor/hydrochlorothiazide combinations: a meta-analysis. International Journal of General Medicine 2012;5:725-34.
33. Kochetkov AI. Thiazide and thiazide-like diuretics in treatment of arterial hypertension: are there any differences? Rational Pharmacotherapy in Cardiology 2020;16(6):994-1001 (In Russian).
34. Ojha U, Ruddaraju S, Sabapathy N, Ravindran V, Worapongsatitaya P, Haq J, Mohammed R, Patel V. Current and emerging classes of pharmacological agents for the management of hypertension. American Journal of Cardiovascular Drugs 2021 Dec 8;1-15. doi: 10.1007/s40256-021-00510-9. Online ahead of print.
35. Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andréjak M; Investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. Journal of Hypertension 2004 Dec;22(12):2379-86.
36. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. The Lancet 2001 Sep;358(9287):1033-41.
37. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. The New England Journal of Medicine 2008 May;358(18):1887-98.
38. Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C; HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled Trial. BMJ 2011 Jan;344:d7541.
39. Farsang C; Picasso Investigators. Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. Blood Pressure 2013 Sep;22(Suppl 1):3-10.
40. Kang S, Wu YF, An N, Ren M. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clinical Therapeutics 2004 Feb;26(2):257-70.
41. Protasov KV, Sinkevich DA, Reshina IV, Zhizhko NV, Logovikova SI, Golubeva LV. [Vascular effects of perindopril arginine and indapamide fixed combination in patients with arterial hypertension]. Kardiologiia 2012;52(9):8-14.
42. Neglia D, Fommei E, Varela-Carver A, Mancini M, Ghione S, Lombardi M, Pisani P, Parker H, D’amati G, Donato L, Camici PG. Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. Journal of Hypertension 2011 Feb;29(2):364-72.
43. Ostroumova TM, Parfenov VA, Ostroumova O, Borisova EV. Effect of indapamide/perindopril fixed-dose combination on 24-hour blood pressure and cognitive functions in treatment-naive middle-aged patients with essential arterial hypertension. Neurology, Neuropsychiatry, Psychosomatics 2018;10(3):19-28 (In Russian).
44. Ostroumova TM, Ostroumova OD, Parfenov VA, Perepelova EM, Perepelov VA, Kochetkov AI. Effect of perindopril/indapamide on cerebral blood flow in middle-aged, treatment-naïve patients with hypertension. Advances in Therapy 2020 Dec;37(12):4930-43.
45. Chalmers J, Joshi R, Kengne AP, MacMahon S. Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE. Journal of Hypertension. Supplement 2008;26(2):S11-5.
46. Farsang C, Dézsi CA, Brzozowska-Villatte R, De Champvallins M, Glezer M, Karpov Y. Beneficial effects of a perindopril/indapamide single-pill combination in hypertensive patients with diabetes and/or obesity or metabolic syndrome: a post hoc pooled analysis of four observational studies. Advances in Therapy 2021;38(4):1776-90.
47. Netchessova TA, Shepelkevich AP, Gorbat TV; NIKA Study Group. Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes. High Blood Pressure & Cardiovascular Prevention 2014 Mar;21(1):63-9.
48. Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. High Blood Pressure & Cardiovascular Prevention 2011 Sep;18(3):107-13.
49. Barrios V, Escobar C, Divison JA, Medialdea F. Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population. Expert Review of Cardiovascular Therapy 2008 Sep;6(8):1063-9.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]